#United States #Washington, D.C. #Rare Diseases #NORD #Becky Quick

NORD Breakthrough Summit 2026: A Pivotal Dialogue on Rare Diseases

The National Organization for Rare Disorders (NORD) is gearing up for an impactful event, the NORD Rare Diseases Orphan Products Breakthrough Summit, scheduled for October 25–27, 2026, in Washington, D.C. This annual summit is designed to address pressing issues around the research, treatment, and policy needs of the rare disease community.

One of the most anticipated discussions at the summit will be moderated by Becky Quick, the well-respected co-anchor of CNBC's Squawk Box and host of CNBC Cures. The session titled “Next Decade of Rare Disease: A CEO Leadership Dialogue” will delve into how scientific advancements can be transitioned into effective patient outcomes. The dialogue will feature a powerhouse lineup of CEOs from leading biopharmaceutical companies, including Alexander Hardy from BioMarin, Renee Gala from Jazz Pharmaceuticals, and Tarek Rabah from Otsuka North America Pharmaceutical, alongside NORD CEO Pam Gavin.

The Significance of the Summit

This year marks the 16th anniversary of the Summit and is particularly timely as the landscape of rare disease treatment evolves. Scientific breakthroughs are paving the way for innovative therapies, but translating these advances into accessible treatment options for patients remains a common hurdle. The session moderated by Quick will explore how effective leadership, strategic partnerships, and enhanced investment in healthcare systems can facilitate this transition.

Pam Gavin, the CEO of NORD, emphasizes the urgency of this dialogue, stating, "The scientific opportunities available today are unprecedented, but we must have the right frameworks in place to ensure these advances reach the patients who need them." Facilitating such discussions is essential for bridging gaps in care and ensuring that treatments for over 30 million Americans living with rare diseases are developed and delivered efficiently.

Focus on Collaboration

Throughout the summit, discussions will highlight the need for collaboration across various sectors, including patient advocacy groups, industry leaders, and regulatory bodies. Each panel discussion will approach critical themes such as emerging therapies, patient engagement, and the investment landscape necessary for driving rare disease innovations.

Special Guests and Sessions

In addition to the panel featuring Quick and the CEO leaders, the summit will also include talks by senior officials from federal health authorities, including Kyle Diamantas, Acting Commissioner of the U.S. Food and Drug Administration, and Jay Bhattacharya, Director of the National Institutes of Health. Their insights will be invaluable as they address regulatory challenges and policy priorities facing the rare disease sphere.

Addressing the Challenge of Scale

During the session, participants will explore the challenge of scaling treatments for a wide range of rare diseases. Each of the biopharmaceutical leaders brings distinct perspectives and experience in navigating the nuances of developing and delivering therapies tailored to the needs of patients suffering from conditions that often lack sufficient research and resources.

Quick's personal connection to the topic as a parent of a child with a rare disease adds a profound layer of understanding and urgency to the conversation. She seamlessly blends her extensive business reporting experience with her passion for advocacy, ensuring that key issues affecting patients are front and center in discussions.

Conclusion

Ultimately, the NORD Rare Diseases Orphan Products Breakthrough Summit aims to inspire actionable strategies that can be implemented across the healthcare landscape, ensuring that advancements in science not only lead to breakthroughs but also translate into meaningful improvements in patient care. With over 900 leaders from various sectors expected to attend, this summit promises to enhance the dialogue necessary for transformative change in rare disease treatments. As Gavin aptly states, we are at a crucial moment that demands bold leadership and innovative thinking to pave the way for future advancements in the care of rare diseases.

For more details on registration and to view the full agenda, please visit NORDSummit.org.